The Mechanisms of Underlying Accelerated Repetitive Transcranial Magnetic Stimulation for Treatment-resistant Depression
Study Details
Study Description
Brief Summary
In this project, the investigators evaluate an accelerated schedule of repetitive transcranial magnetic stimulation for treatment-resistant depression. The investigators focuse on participants' brain activity and blood markers (Reelin, Apoer2, NMDAR, BDNF, exosomes and so on) to deepen the understanding of the mechanism of accelerated rTMS for treatment-resistant depression.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
In this project, the investigator evaluate an accelerated schedule of repetitive transcranial magnetic stimulation for treatment-resistant depression. Patients were included in two groups and received an accelerated stimulation or sham treatment. The changes of neuroimaging and biomarkers at baseline, 5 days after treatment and 1 month after treatment are evaluated. The investigators focuse on participants' brain activity and blood markers (Reelin, Apoer2, NMDAR, BDNF, exosomes and so on) to deepen the understanding of the mechanism of accelerated rTMS for treatment-resistant depression.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: active iTBS The active group of TRD will receive the accelerated intermittent TBS(iTBS).The iTBS cycles including 10 bursts of three pulses at 50 Hz were delivered in 2-second trains. Each iTBS session comprised 60 x 2 second trains, with an 8-second intertrain interval and total duration of 10-minutes.Treatment sessions were administered hourly 10 times a day totaling 18,000 pulses/day. Patients received this treatment protocol for 5 consecutive days (90,000 pulses in total). |
Device: active iTBS
Participants in the active stimulation group will receive the accelerated intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the neuronavigation system. Stimulation intensity will be standardized at 90% of RMT.
Stimulation will be delivered to the L-DLPFC using an NTK-TMS-II100 TMS device,is compatible with the Brainsight TMS navigation system.
|
| Sham Comparator: sham rTMS The sham group of TRD will receive sham rTMS stimulation. |
Device: sham rTMS
The parameters in the sham arm will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
|
Outcome Measures
Primary Outcome Measures
- Change in remission rate of Hamilton Depression Scale (24-items) (HAM-D24) score after treatment. [Baseline, 5-day, 1-month]
The Hamilton Depression Scale (24-items) (HAM-D24), is a 24 item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders. Higher HAM-D24 score indicates more severe depression, and each item yields a score of 0 to 4. Remission is defined as HAM-D24 ≤8.
Secondary Outcome Measures
- Change in response rate of Hamilton Depression Scale (24-items) (HAM-D24) score after treatment. [Baseline, 5-day, 1-month]
The Hamilton Depression Scale (24-items) (HAM-D24), is a 24 item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders. Higher HAM-D24 score indicates more severe depression, and each item yields a score of 0 to 4. Response is defined as a reduction of >/=50% of HAM-D24 baseline score.
- Change in the rate of Beck Scale of Suicidal Ideation score after treatment. [Baseline, 5-day, 1-month]
Beck Scale of Suicidal Ideation(BSI) is a 21-item self-report instrument that detects and measures the intensity of a patient's specific attitudes, behaviors, and suicide plans during the past week.
- Change in the rate of Hamilton Anxiety Scale score after treatment. [Baseline, 5-day, 1-month]
Hamilton Anxiety Scale (HAMA) is a 17 item diagnostic questionnaire used to measure the severity of anxiety episodes in patients
Eligibility Criteria
Criteria
Inclusion Criteria:
-
The current episode met the DSM-5 diagnostic criteria for major depression in patients with first-episode or relapsed unmedicated depression without psychotic symptoms.
-
24-item Hamilton Depression Scale (HAMD-24) ≥ 20.
-
Age 18-45 years, regardless of gender.
-
Right-handedness.
-
Han Chinese.
-
Signed a written informed consent, willing to participate in the study and be evaluated.
Exclusion Criteria:
-
Co-morbid other mental disorders, including: schizophrenia, mental retardation, substance dependence, etc.
-
Patients with metal objects in the body or with other contraindications to MRI scanning
-
Patients with severe or unstable somatic diseases
-
Women during pregnancy or lactation, and women of childbearing age with positive urine HCG test results during the screening period
-
Other conditions that, in the opinion of the investigator, exist that make participation in this clinical trial inappropriate.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | The First Affiliated Hospital of Zhejiang University | Hangzhou | Zhejiang | China | 310000 |
Sponsors and Collaborators
- First Affiliated Hospital of Zhejiang University
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 82271562